Sarcoidosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Sarcoidosis

Sarcoidosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Sarcoidosis is an inflammatory disease characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organs of the body. Radiologic Staging of Sarcoidosis:

Stage 0- Normal

Stage I-Bilateral hilar lymphadenopathy

Stage II- Bilateral hilar lymphadenopathy and pulmonary infiltrates

Stage III- Pulmonary infiltrates without bilateral hilar lymphadenopathy

Stage IV- Pulmonary fibrosis

Epidemiology-

Thelansis estimated that the prevalence of sarcoidosis in the US ranges between 150,000 and 200,000, with an estimated 1.2 million individuals with sarcoidosis worldwide.

Competitive landscape of Sarcoidosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Sarcoidosis across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Sarcoidosis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Sarcoidosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        ATYR1923        aTyr Pharma, Inc.        Phase 2

2        CMK389        Novartis Pharmaceuticals        Phase 2

3        ARA 290        Araim Pharmaceuticals, Inc.        Phase 2

4        Selexipag        Actelion        Phase 2

5        Ambrisentan        Gilead Sciences        Phase 3

6        iNO        Bellerophon        Phase 2

7        Tofacitinib        Pfizer        Phase 1

8        18F-FSPG        GE Healthcare        Phase 2

9        Inhaled Treprostinil        United Therapeutics        Phase 2

10        Ursodeoxycholic Acid        Exalenz Bioscience LTD.        Phase 2

11        Bardoxolone methyl        Reata Pharmaceuticals, Inc.        Phase 2